Our Financial Interactions in Health Care, 2020
The Voluntary Framework on Disclosure of Payments was developed by Innovative Medicines Canada. As a partner in Canada’s health care system, Lilly Canada regularly collaborates with health care professionals (HCPs) and health care organizations (HCOs) to foster scientific exchange, for the ultimate benefit of patients. These collaborations are bound by local and international laws, and are regulated by Innovative Medicines Canada's Code of Ethical Practices. Lilly’s decision to publish our payments to HCPs and HCOs is a voluntary part of our overall commitment to greater transparency and high ethical standards in our business practices.
All payment information has been captured in aggregate form (one sum total) and presented below in three categories:
Beyond the voluntary framework established by Innovative Medicines Canada, Lilly Canada is also publishing that, during this period, we spent
For clarity, please note the following:
Taxes are excluded wherever possible and all funds are in Canadian dollars
These sums are captured according to payment dates and not necessarily the dates on which the activity occurred. Therefore, some activities in the previous reporting period are published here, and some activities that occurred during this reporting period will be published in the next report;
Some payments made to HCOs include payments that were passed through to HCPs as fees for services; in such cases, the fees are reported in the sum of our funding of HCOs;
Total funding to HCOs also includes payments to Patient Associations;
Lilly has used our reasonable best efforts to capture the most comprehensive data possible according to our knowledge and interpretation of the Voluntary Framework on the Disclosure Payments to HCPs/HCOs.
Legal Disclaimer: While Lilly makes every effort to present accurate and reliable information, we make no warranty and assume no legal liability or responsibility for the accuracy or completeness of the information contained herein.